Xeroderma Pigmentosum: 11 Clinical Trials, Page 1 of 2

1 2

Hide Studies Not Open or Pending


Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Condition(s):Constitutional Mismatch Repair Deficiency Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Lynch Syndrome; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Primary Central Nervous System Neoplasm; Xeroderma PigmentosumLast Updated:November 23, 2021Recruiting

1 2

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.